SERUM C-REACTIVE PROTEIN IN WOMEN WITH PREECLAMPSIA

THESIS SUMITTED FOR
FULFILLMENT OF M.S.c DEGREE IN
OBSTETRICS & GYNECOLOGY
by

Shimaa Mostafa Abd Al Fattah M.B.B.CH.

Resident of Obstetrics and Gynecology kasr AL-Aini hospital Supervised by

Dr. Mohamed Hany Shehata
Professor of Obstetrics and Gynecology
Cairo University

Dr. Mohamed Hamam Abd Manaf
Lecturer of Obstetrics and Gynecology
Cairo University

Dr. Sarah Adel Labeb
Lecturer of clinical pathology
Cairo University

Faculty of Medicine Cairo University 2011



Abstract

Pregnancy induced hypertension (PIH) is the most frequent complication in pregnancy after the 20th week of gestation. This form of hypertension is classified as preeclampsia (PE) and gestational hypertension (GH). The latter is defined as the acute development of hypertension in a woman whose blood pressure (BP) was normal in the early stages of pregnancy and who subsequently developed persistent elevation of BP to at least 140/90 mmHg. Both GH and concomitant 24 hours Proteinuria (0.3 gm/L or more) in the absence of urinary tract infection is defined as PE (*Ronald et al.*, 2007).

The condition of PE is the main cause of maternal and perinatal mortality (Buchbinder et al., 2002).

Preeclampsia develops in 4–5% of human pregnancies. It is characterized by an elevated blood pressure and Proteinuria and develops after 20 weeks of gestational age. PE can result in eclampsia when convulsions develop or manifest as the hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome. (*Van Wijk et al.*, 2000).

Several etiologies have been implicated in the development of preeclampsia. Endothelial dysfunction or inappropriate endothelial cell activation are the most common clinical manifestations in preeclampsia, including enhanced endothelial-cell permeability and platelet aggregation (*Wang et al., 2004*).

Endothelial dysfunction is accompanied by elevated levels of inflammatory markers such as CRP (*Teran et al.*, 2001). C-reactive protein (CRP) is an objective and sensitive index of overall inflammatory activity in the body (*Kluft and Maat*, 2002). There had been a growing interest in the role of inflammation as a key factor of endothelial dysfunction. A generalized activation of circulating leukocytes, characteristic of inflammation, has been found during preeclampsia (*Redman et al.*, 1999).

Key words: SERUM C-REACTIVE PROTEIN - WOMEN WITH PREECLAMPSIA

ACKNOWLEDGEMENT

First and above of all, thanks to the merciful ALLAH for helping me to finish this work, and for the great countless gifts I have been offered throughout my life, then my family; my father, my mother, my sisters and my brother for their continuous encouragement, support and praying that lights my way throughout my life.

It is a great honor to express my sincere thanks, deep gratitude and appreciation to Prof. Dr. Mohamed Hany Shehata Professor of Obstetrics & Gynecology, Faculty of Medicine, Cairo University for his encouragement, creative suggestions, fatherhood and whole hearted support, both scientific and moral and for his valuable guidance throughout this work.

My words fail to express my sincere thanks and deep gratitude to Dr. Mohamed Hamam Abd Manaf Lecturer of Obstetrics & Gynecology, Faculty of Medicine, Cairo University for his energetic help spending long hours in careful review of this work following its details with constructive advice and criticism.

I would like to express my sincere appreciation to Dr.Sarah Adel Labib lecturer of Clinical Pathology, Faculty of Medicine, Cairo University for her kind encouragement and great help in performing this study.

Finally, I can never forget to express the profound thanks and appreciation to all my friends who helped me with special thanks to my family, for their great effort and support they offered in performing this work.

Shimaa Mostafa Abd Al Fattah.

List of Contents

	Page
Abstract	1
Introduction	2
Aim of the Work	5
Review of Literature:	7
Chapter (1): Preeclampsia	8
Chapter (2): C-reactive protein	54
Patients and Methods	64
Results	70
Discussion	81
Conclusion and Recommendations	87
Summary	89
References	94
Arabic Summary	116

List of Tables

	Table Page
Table 1:	Differences between mild an sever preeclampsia29
Table 2:	Methods to prevent preeclampsia36
Table 3:	Doses of most commonly used agents used for treatment of BP>160/110mmHg
Table 4:	Doses of most commonly used agents used for treatment of BP
	140-159/90-105mmHg
Table 5:	Intrapartum management of preeclampsia49
Table 6:	Comparison between control group and preeclampsia(PET) group of patient as regarding descriptive data(<i>Age</i> , <i>GA</i> , <i>BMI</i>):71
Table 7:	Comparison between control group and preeclampsia(PET) group of patient as regarding descriptive data(SBP&DBP)
Table 8:	Comparison between control group and preeclamptic group as regarding degree of albuminuria
Table 9:	Comparison between control group and preeclampsia group as regarding the degree of albuminuria using Chi-Square test
Table 10:	Comparison between control group and preeclamptic group as regarding serum CRP levels(mg/L)
Table 11:	Comparison between control group and preeclamptic group as regarding serum CRP levels (mg/l)using Chi-Square test

Table 12:	Correlation matrix between CRP and CRP, SBP& DBP in the control
	group
Table 13:	Correlation matrix between CRP and CRP, SBP, DBP & albuminuria in the preeclamptic group
Table 14:	Diagnostic validity criteria for evaluation of CRP to discriminate preeclampsia group from control group at each cut of value79

List of Figures

Figure	Page
Figure1: Normal& Abnormal p	lacentation 14
Figure 2: Normal uterine Dopp	ler wave form at 24 weeks gestation
	44
gestation in hypertensiv superimposed	e Doppler wave form at 24 week e patient who later develop form pregnancy induced
Figure 4: Crystal structure of C-1 phosphocholine form	reactive protein complex with57
Figure 5: Model of interaction of	CRP with complement58
	n patients (preeclamptic)& control groups as72
_	atients (preeclamptic)& control group age(weeks72
Figure (8): Comparison between group as regarding BMI (1	
_	patients(preeclamptic)& control SBP74
_	n patients (preeclamptic) and control groups as ee of albuminuria75

Figure (11): Comparison between patients (preeclamptic) and control groups as regarding the serum CRP titer
Figure (12) : Diagnostic validity criteria for evaluation of CRP to discriminate preeclamptic group from Control group at conc. 6
mg/L 80
Figure (13): ROC(receiver operating characteristics) curve analysis showing
the diagnostic performance of CRP for discriminating pregnancy
with pre-eclampsia from those
without80

List of abbreviations

ACE: angiotensin converting enzyme

ACOG: American College of Obstetricians and Gynecologists

AFP: Alfa feto-protein.

ANP: Atrial natruretic peptide

ARBs: angiotensin receptor blocker

AT: Angiotesin

b.i.d: two times daily.

BMI: Body Mass Index

CRP: C-reactive protein

CVD: cardiovascular

DBP: diastolic blood pressure

DIC: disseminated intravascular coagulopathy.

Eff: efficacy

FHR: fetal heart rate

FN: false negative.

GA: Gestation Age.

GFR: glomerular filtration rate.

GH: gestational hypertension.

HCG: Human Chorionic Goanadotrophin

HDL: High-Density Lipoprotein.

HLA: Human Leucocytic Antigen

HPL: Human Placental Lactogen

Ht: height.

IL: Interleukin

IRR: incidence rate ratio.

IUGR: Intra Uterine Growth Restriction

LDH: lactate dehydrogenase.

LDL: low-Density Lipoprotein.

MAP: Mean arterial pressure

NDL: non diagnostic line.

NHBPEP: National High Blood Pressure Education Program

NK: Natural Killer

NOS: Nitric Oxide Synthetase.

PA preparation: intermediate release preparation.

PA: Plsminogen Activators.

PAF: Platelet Activating Factor

PAI: plasminogen activator inhibitor.

PE: preeclampsia

PECAM-1: Platelet Endothelial Cell Adhesion Molecule-1

PGF: placental growth factor.

PIH: Pregnancy Induced Hypertension

PO: per oral.

PROM: premature rupture of membrane.

ROC: receiver operating characteristic.

SAA: serum amyloid A protein

SAP: serum amyloid P component.

SBP: systolic blood pressure

SD: Standard Deviation

SGOT: Serum Glutamic-Oxaloacetic Transaminase.

SGPT: Serum Glutamic-Pyruvic Transaminase

SL preparation: slow release preparation.

SN: Sensitivity.

SP: specificity

t.i.d: three times daily.

TAT: thrombin-antithrombinIII complex.

TNF: Tumor Necrosis Factor

TP: true positive.

TTP: thrombotic thrombocytopenic purpura.

VEGF: vascular endothelial growth factor

Wt; weight.

XL: extended release preparation.



Introduction

INTRODUCTION

Pregnancy induced hypertension (PIH) is the most frequent complication in pregnancy after the 20th week of gestation. This form of hypertension is classified as preeclampsia (PE) and gestational hypertension (GH). The latter is defined as the acute development of hypertension in a woman whose blood pressure (BP) was normal in the early stages of pregnancy and who subsequently developed persistent elevation of BP to at least 140/90 mmHg. Both GH and concomitant 24 hours Proteinuria (0.3 gm/L or more) in the absence of urinary tract infection is defined as PE (*Ronald et al.*, 2007).

The condition of PE is the main cause of maternal and perinatal mortality, low birth weight, and intrauterine growth restriction, whereas GH has been associated with increased rates of preterm delivery and small for gestational age infants (*Buchbinder et al.*, 2002).

Preeclampsia develops in 4–5% of human pregnancies. It is characterized by an elevated blood pressure and Proteinuria and develops after 20 weeks of gestational age. PE can result in eclampsia when convulsions develop or manifest as the hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome. Both eclampsia and HELLP syndrome are known to be associated with severe complications such as cerebral hemorrhage, lung edema, renal insufficiency, and liver hemorrhage (*Van Wijk et al.*, 2000).

Several etiologies have been implicated in the development of preeclampsia. Some of them include abnormal trophoblast invasion of uterine blood vessels, immunological intolerance between fetoplacental and maternal tissues, maladaptation to the cardiovascular changes or dietary deficiencies and genetic abnormalities (*Sibai*, 2003). Endothelial dysfunction or inappropriate endothelial cell activation are the most common clinical manifestations in

preeclampsia, including enhanced endothelial-cell permeability and platelet aggregation (Wang et al., 2004).

Endothelial dysfunction is accompanied by elevated levels of inflammatory markers such as CRP (*Teran et al.*, 2001). C-reactive protein (CRP) is an objective and sensitive index of overall inflammatory activity in the body (*Kluft and Maat*, 2002). There had been a growing interest in the role of inflammation as a key factor of endothelial dysfunction. A generalized activation of circulating leukocytes, characteristic of inflammation, has been found during preeclampsia (*Redman et al.*, 1999).

In a cross sectional study, that was conducted at the Yuzuncu Yil University, Medical Faculty, Department of Obstetrics and Gynecology over a one year period on 112 primigravidas patients with gestational age 28–40 weeks, it was found that serum CRP levels were higher in women with PE than normotensive pregnant women at week 32 (5.1 mg/l versus 2.2 mg/l, P = 0.0007), and also were higher at delivery (5.9 mg/l versus 2.5 mg/l, P = 0.001) (*Yusuf et al.*, 2005).

Another study, that was conducted at Severance Hospitals of Yonsei University Medical Center, Seoul, Korea on 202 healthy pregnant normotensive women and 25 women with severe PE, it had been reported that serum CRP levels were higher in preeclamptic women than in healthy pregnant normotensive women (*Hwang et al.*, 2007).